Literature DB >> 21931239

Screening for understanding of research in the inpatient psychiatry setting.

Norval J Hickman1, Judith J Prochaska, Laura B Dunn.   

Abstract

People with mental illness constitute a substantial proportion of smokers and an important population for smoking cessation research. Obtaining informed consent in this population is a critical ethical endeavor. We examined performance on a three-item instrument (3Q) designed to screen for understanding of several key elements of research: study purpose, risks, and benefits. Patients were clinically diagnosed with primary unipolar depression (n = 40), a primary psychotic disorder (n = 32), both mood and psychotic disorders (n = 17), and primary bipolar disorder (n = 14). Among an ethnically diverse sample of 124 psychiatric inpatients approached for a smoking cessation trial, 107 (86%) performed adequately on the 3Q (i.e., obtained a score of at least 3 out of a possible 6). Patients were better able to identify the study risks and benefits than to describe the study purpose. The 3Q appears to be a useful tool for researchers working with vulnerable psychiatric patients.

Entities:  

Mesh:

Year:  2011        PMID: 21931239      PMCID: PMC3357117          DOI: 10.1525/jer.2011.6.3.65

Source DB:  PubMed          Journal:  J Empir Res Hum Res Ethics        ISSN: 1556-2646            Impact factor:   1.742


  26 in total

1.  Therapeutic misconception and the appreciation of risks in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Thomas Grisso; Michelle Renaud
Journal:  Soc Sci Med       Date:  2004-05       Impact factor: 4.634

2.  Improving informed consent and enhancing recruitment for research by understanding economic behavior.

Authors:  Laura B Dunn; Nora E Gordon
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

3.  Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument.

Authors:  Barton W Palmer; Laura B Dunn; Paul S Appelbaum; Sunder Mudaliar; Leon Thal; Robert Henry; Shahrokh Golshan; Dilip V Jeste
Journal:  Arch Gen Psychiatry       Date:  2005-07

Review 4.  The ethical basis of psychiatric research: conceptual issues and empirical findings.

Authors:  L W Roberts
Journal:  Compr Psychiatry       Date:  1998 May-Jun       Impact factor: 3.735

5.  Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation.

Authors:  L W Roberts; T D Warner; J L Brody
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

Review 6.  Consent in impaired populations.

Authors:  Paul S Appelbaum
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

7.  Enhancing informed consent for research and treatment.

Authors:  L B Dunn; D V Jeste
Journal:  Neuropsychopharmacology       Date:  2001-06       Impact factor: 7.853

8.  Capacity to provide informed consent for participation in schizophrenia and HIV research.

Authors:  David J Moser; Susan K Schultz; Stephan Arndt; Michelle L Benjamin; Frank W Fleming; Colleen S Brems; Jane S Paulsen; Paul S Appelbaum; Nancy C Andreasen
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

9.  Willingness and competence of depressed and schizophrenic inpatients to consent to research.

Authors:  Bruce J Cohen; Elizabeth L McGarvey; Relana C Pinkerton; Ludmila Kryzhanivska
Journal:  J Am Acad Psychiatry Law       Date:  2004

10.  Correlates of treatment-related decision-making capacity among middle-aged and older patients with schizophrenia.

Authors:  Barton W Palmer; Laura B Dunn; Paul S Appelbaum; Dilip V Jeste
Journal:  Arch Gen Psychiatry       Date:  2004-03
View more
  8 in total

1.  Treating Smoking in Adults With Co-occurring Acute Psychiatric and Addictive Disorders.

Authors:  Smita Das; Norval J Hickman; Judith J Prochaska
Journal:  J Addict Med       Date:  2017 Jul/Aug       Impact factor: 3.702

2.  Treating Tobacco Dependence at the Intersection of Diversity, Poverty, and Mental Illness: A Randomized Feasibility and Replication Trial.

Authors:  Norval J Hickman; Kevin L Delucchi; Judith J Prochaska
Journal:  Nicotine Tob Res       Date:  2015-08       Impact factor: 4.244

3.  Multiple risk-behavior profiles of smokers with serious mental illness and motivation for change.

Authors:  Judith J Prochaska; Sebastien C Fromont; Kevin Delucchi; Kelly C Young-Wolff; Neal L Benowitz; Stephen Hall; Thomas Bonas; Sharon M Hall
Journal:  Health Psychol       Date:  2014-01-27       Impact factor: 4.267

4.  Maximizing retention with high risk participants in a clinical trial.

Authors:  Romina Kim; Norval Hickman; Kathleen Gali; Nicholas Orozco; Judith J Prochaska
Journal:  Am J Health Promot       Date:  2013-07-22

5.  Adolescents with substance use disorder and assent/consent: Empirical data on understanding biobank risks in genomic research.

Authors:  Marilyn E Coors; Kristen M Raymond; Christian J Hopfer; Joseph Sakai; Shannon K McWilliams; Susan Young; Susan K Mikulich-Gilbertson
Journal:  Drug Alcohol Depend       Date:  2015-12-21       Impact factor: 4.492

6.  Smokers with serious mental illness and requests for nicotine replacement therapy post-hospitalisation.

Authors:  Rachel K Schuck; Audun Dahl; Sharon M Hall; Kevin Delucchi; Sebastien C Fromont; Stephen E Hall; Thomas Bonas; Judith J Prochaska
Journal:  Tob Control       Date:  2014-09-10       Impact factor: 7.552

7.  E-cigarette use among smokers with serious mental illness.

Authors:  Judith J Prochaska; Rachel A Grana
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

8.  Impact of COVID-19 Mitigation Efforts on Adults With Serious Mental Illness: A Patient-Centered Perspective.

Authors:  Ivy Benjenk; Zeina Saliba; Neel Duggal; Asmaa Albaroudi; Jacqueline Posada; Jie Chen
Journal:  J Nerv Ment Dis       Date:  2021-12-01       Impact factor: 2.254

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.